These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23904864)

  • 41. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A patent review on cathepsin K inhibitors to treat osteoporosis (2011 - 2021).
    Rocho FR; Bonatto V; Lameiro RF; Lameira J; Leitão A; Montanari CA
    Expert Opin Ther Pat; 2022 May; 32(5):561-573. PubMed ID: 35137661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans.
    Kassahun K; McIntosh I; Koeplinger K; Sun L; Talaty JE; Miller DL; Dixon R; Zajic S; Stoch SA
    Drug Metab Dispos; 2014 May; 42(5):818-27. PubMed ID: 24553380
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences.
    Brömme D; Panwar P; Turan S
    Expert Opin Drug Discov; 2016; 11(5):457-72. PubMed ID: 27001692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strontium ranelate: a new paradigm in the treatment of osteoporosis.
    Reginster JY; Deroisy R; Jupsin I
    Drugs Today (Barc); 2003 Feb; 39(2):89-101. PubMed ID: 12698204
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A supra-cellular model for coupling of bone resorption to formation during remodeling: lessons from two bone resorption inhibitors affecting bone formation differently.
    Jensen PR; Andersen TL; Pennypacker BL; Duong LT; Engelholm LH; Delaissé JM
    Biochem Biophys Res Commun; 2014 Jan; 443(2):694-9. PubMed ID: 24333871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging Therapies for Osteoporosis.
    McClung MR
    Endocrinol Metab (Seoul); 2015 Dec; 30(4):429-35. PubMed ID: 26354487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis.
    Binkley N; Orwoll E; Chapurlat R; Langdahl BL; Scott BB; Giezek H; Santora AC
    Osteoporos Int; 2021 Jan; 32(1):173-184. PubMed ID: 33200257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial.
    Engelke K; Fuerst T; Dardzinski B; Kornak J; Ather S; Genant HK; de Papp A
    J Bone Miner Res; 2015 Jan; 30(1):30-8. PubMed ID: 24898537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New therapeutical horizons in the management of postmenopausal osteoporosis.
    Migliaccio S; Fornari R; Greco EA; Di Luigi L; Lenzi A
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S117-9. PubMed ID: 24048905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
    Duong LT; Crawford R; Scott K; Winkelmann CT; Wu G; Szczerba P; Gentile MA
    Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
    Langdahl B; Binkley N; Bone H; Gilchrist N; Resch H; Rodriguez Portales J; Denker A; Lombardi A; Le Bailly De Tilleghem C; Dasilva C; Rosenberg E; Leung A
    J Bone Miner Res; 2012 Nov; 27(11):2251-8. PubMed ID: 22777865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cathepsin K: The Action in and Beyond Bone.
    Dai R; Wu Z; Chu HY; Lu J; Lyu A; Liu J; Zhang G
    Front Cell Dev Biol; 2020; 8():433. PubMed ID: 32582709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
    Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
    Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
    Jensen AB; Wynne C; Ramirez G; He W; Song Y; Berd Y; Wang H; Mehta A; Lombardi A
    Clin Breast Cancer; 2010 Dec; 10(6):452-8. PubMed ID: 21147688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
    Eisman JA; Bone HG; Hosking DJ; McClung MR; Reid IR; Rizzoli R; Resch H; Verbruggen N; Hustad CM; DaSilva C; Petrovic R; Santora AC; Ince BA; Lombardi A
    J Bone Miner Res; 2011 Feb; 26(2):242-51. PubMed ID: 20740685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate.
    Li Z; Hou WS; Escalante-Torres CR; Gelb BD; Bromme D
    J Biol Chem; 2002 Aug; 277(32):28669-76. PubMed ID: 12039963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
    Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W
    J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M; Reyes-García R; Mezquita-Raya P; Fernández-García D; Alonso G; Luna Jde D; Ruiz-Requena ME; Escobar-Jiménez F
    Maturitas; 2009 Nov; 64(3):188-92. PubMed ID: 19819089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.